Page last updated: 2024-12-07
4-methylaminorex
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4-methylaminorex: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 92196 |
SCHEMBL ID | 10385231 |
MeSH ID | M0040081 |
PubMed CID | 3058692 |
CHEMBL ID | 4781888 |
SCHEMBL ID | 10385712 |
MeSH ID | M0040081 |
Synonyms (59)
Synonym |
---|
2-oxazoline, 2-amino-4-methyl-5-phenyl- |
2-oxazolamine, 4,5-dihydro-4-methyl-5-phenyl- |
2-amino-4-methyl- 5-phenyloxazoline |
2-amino-4-methyl-5-phenyl-2-oxazoline |
DB01447 |
4-methylaminorex |
4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine |
3568-94-3 |
4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine |
7pk6vc94ou , |
unii-7pk6vc94ou |
SCHEMBL10385231 |
LJQBMYDFWFGESC-UHFFFAOYSA-N |
4-methyl-5-phenyl-4,5-dihydrooxazol-2-amine |
FT-0671491 |
Q230007 |
DTXSID30860432 |
4-mar, 4-max |
PD008857 |
4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine; 2-amino-4-methyl-5-phenyl-2-oxazoline; mcn 822; 4-methyl aminorex |
dea no. 1590 |
75493-87-7 |
j5g5n6r0tm , |
unii-j5g5n6r0tm |
((+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine) |
(4s,5r)-4-methylaminorex |
(+/-)cis-4-methylaminorex |
(-)-cis-1-imino-4-methyl-5-phenyloxazolidine |
mcn-822 |
oxazolidine, 1-imino-4-methyl-5-phenyl- (z)-(-)- |
NCGC00247671-01 |
4-methylaminorex, (4s,5r)- |
u4euh |
mcn-422 |
tox21_112818 |
cas-29493-77-4 |
dtxsid2048870 , |
dtxcid101349408 |
2-oxazolamine, 4,5-dihydro-4-methyl-5-phenyl-, (4s,5r)- |
4-methylaminorex, (4s-cis)- |
SCHEMBL10385712 |
4-methylaminorex (cis) |
cis-4-methylaminorex |
cis-(.+/-.)-4-methylaminorex |
LJQBMYDFWFGESC-CBAPKCEASA-N |
4-methylaminorex (+/-)-cis-form [mi] |
(+/-)-cis-2-amino-4-methyl-5-phenyl-2-oxazoline |
2-oxazolamine, 4,5-dihydro-4-methyl-5-phenyl-, (4r,5s)-rel- |
2149qzm652 , |
unii-2149qzm652 |
4-methylaminorex, cis-(+/-)- |
(+/-)-cis-4-methylaminorex |
2-oxazoline, 2-amino-4-methyl-5-phenyl-, cis-(+/-)- |
eu4ea |
2-oxazolamine, 4,5-dihydro-4-methyl-5-phenyl-, cis-(+/-)- |
(+/-)-cis-mcn-822 |
4-methylaminorex (cis isomer) |
CHEMBL4781888 |
DTXSID301345890 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" This study characterized their pharmacokinetic and tissue distribution profiles, and metabolic turnover to norephedrine and norpseudoephedrine, in male Wistar rats." | ( Pharmacokinetics and tissue distribution of the stereoisomers of 4-methylaminorex in the rat. Bardy, A; Ellermaa, S; Kankaanpää, A; Meririnne, E; Seppälä, T, 2004) | 0.56 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"0 min, elimination half-life 35-42 min, and bioavailability 32-57% intraperitoneally or 4-16% orally), whereas trans-4R,5R-isomer differed from the others, with a longer elimination half-life (118-169 min) and higher bioavailability (100% intraperitoneally or 83% orally)." | ( Pharmacokinetics and tissue distribution of the stereoisomers of 4-methylaminorex in the rat. Bardy, A; Ellermaa, S; Kankaanpää, A; Meririnne, E; Seppälä, T, 2004) | 0.56 |
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Dosage Studied
4-methylaminorex manifested a very steep dose-response curve. The duration of convulsive activity was shortest for cocaine and longest for methamphetamine. No changes in striatal tyrosine hydroxylase were observed 7 days after acute or multiple dosing with this drug.
Excerpt | Relevance | Reference |
---|---|---|
" In contrast, although a decline in striatal tyrosine hydroxylase occurred 3 h following a single dose of 4-methylaminorex, no changes in this enzyme were observed at 7 days after acute or multiple dosing with this drug." | ( Response of monoaminergic and neuropeptide systems to 4-methylaminorex: a new stimulant of abuse. Bunker, CF; Bush, L; Gibb, JW; Hanson, GR; Johnson, M, 1992) | 0.75 |
" Thus, dose-response and time-response studies were conducted in order to assess the effects of this drug on monoaminergic and neuropeptide systems in extrapyramidal and limbic structures." | ( Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse. Bunker, CF; Bush, LG; Gibb, JW; Hanson, GR; Johnson, M, 1990) | 0.53 |
" Solid dosage samples of U4EuH were analyzed using gas chromatography, ultraviolet and infrared spectroscopy, nuclear magnetic resonance, and mass spectrometry." | ( A fatality involving U4Euh, a cyclic derivative of phenylpropanolamine. Brewster, ME; Davis, FT, 1988) | 0.27 |
" The features of the stimulant-induced seizures were distinct and included the following: (1) the duration of convulsive activity was shortest for cocaine and longest for methamphetamine, (2) only MDMA produced a secondary clonic phase after the initial ictal event, and (3) 4-methylaminorex manifested a very steep dose-response curve." | ( Distinct features of seizures induced by cocaine and amphetamine analogs. Hanson, GR; Jensen, M; Johnson, M; White, HS, 1999) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 3.0232 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
TDP1 protein | Homo sapiens (human) | Potency | 67.1970 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 14.1961 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 61.3569 | 0.0030 | 41.6115 | 22,387.1992 | AID1159553; AID1159555 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 9.0366 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
cytochrome P450 2D6 | Homo sapiens (human) | Potency | 4.9186 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
Interferon beta | Homo sapiens (human) | Potency | 66.5024 | 0.0033 | 9.1582 | 39.8107 | AID1347407 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (30)
Molecular Functions (5)
Process | via Protein(s) | Taxonomy |
---|---|---|
cytokine activity | Interferon beta | Homo sapiens (human) |
cytokine receptor binding | Interferon beta | Homo sapiens (human) |
type I interferon receptor binding | Interferon beta | Homo sapiens (human) |
protein binding | Interferon beta | Homo sapiens (human) |
chloramphenicol O-acetyltransferase activity | Interferon beta | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Ceullar Components (2)
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular space | Interferon beta | Homo sapiens (human) |
extracellular region | Interferon beta | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Bioassays (33)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (26)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (3.85) | 18.7374 |
1990's | 9 (34.62) | 18.2507 |
2000's | 5 (19.23) | 29.6817 |
2010's | 4 (15.38) | 24.3611 |
2020's | 7 (26.92) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 39.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.15) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (10.00%) | 4.05% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Observational | 0 (0.00%) | 0.25% |
Other | 18 (90.00%) | 84.16% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |